Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$225.25
-0.6%		$245.06
$186.05
▼
$282.15
$14.05B0.38703,954 shs680,312 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$62.23
-1.0%		$56.73
$33.76
▼
$63.39
$15.42B0.472.61 million shs2.64 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$14.63
-4.8%		$15.74
$12.07
▼
$29.23
$11.70B-1.514.63 million shs4.31 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+62.69%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.17%+1.76%-5.48%-13.17%+9.41%
Exelixis, Inc. stock logo
EXEL
Exelixis
+3.02%+6.46%+10.42%+12.36%+56.96%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.59%-10.48%-11.67%+11.30%-32.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$225.25
-0.6%		$245.06
$186.05
▼
$282.15
$14.05B0.38703,954 shs680,312 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$62.23
-1.0%		$56.73
$33.76
▼
$63.39
$15.42B0.472.61 million shs2.64 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$14.63
-4.8%		$15.74
$12.07
▼
$29.23
$11.70B-1.514.63 million shs4.31 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+62.69%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-0.17%+1.76%-5.48%-13.17%+9.41%
Exelixis, Inc. stock logo
EXEL
Exelixis
+3.02%+6.46%+10.42%+12.36%+56.96%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.59%-10.48%-11.67%+11.30%-32.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.14
Hold$38.88-5.25% Downside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$309.2637.30% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.79-18.39% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.58
Moderate Buy$28.6195.54% Upside

Current Analyst Ratings Breakdown

Latest APLS, EXEL, ASND, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$307.00 ➝ $269.00
10/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold (C)
10/9/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Perform$45.00 ➝ $51.00
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (A-) ➝ Buy (A)
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$46.00 ➝ $45.00
10/7/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$52.00 ➝ $54.00
10/5/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/30/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$1.11B4.75$0.21 per share196.33$3.24 per share12.66
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.25N/AN/A($2.97) per share-75.84
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.65$3.09 per share20.15$8.06 per share7.72
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.4725.17N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1819.5716.771.7135.33%42.17%31.76%11/3/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest APLS, EXEL, ASND, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.9080N/AN/AN/A$411.29 millionN/A
11/3/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8790N/AN/AN/A$646.95 millionN/A
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2806N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.87
3.63
3.16
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770128.02 million119.70 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.73 million131.96 millionOptionable

Recent News About These Companies

Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)
October 13 at 3:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-summit-therapeutics-sees-unusually-large-options-volume-nasdaq-smmt-2026-10-13/
Summit Therapeutics (NASDAQ:SMMT) Shares Down 5.8% - Here's What Happened
October 13 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-down-58-heres-what-happened-2026-10-13/
Summit Therapeutics (SMMT) Projected to Release Earnings on Monday
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109071
Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday
October 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-summit-therapeutics-smmt-set-to-release-quarterly-earnings-on-monday-2026-10-12/
Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-jumps-36-whats-next-2026-10-07/
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
October 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3000206/smmt-inks-deal-with-azn-daiichi-to-study-ivonescimab-datroway-combos?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3000206
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-7-3-230615020.html
Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696045/daiichi-sankyo-astrazenca-summit-partner-to-evaluate-datroway-plus-ivonescimab.aspx
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001197318/en/summit-therapeutics-announces-clinical-trial-collaboration-with-astrazeneca-and-daiichi-sankyo-to-evaluate-ivonescimab-in-combination-with-trop2-directed-adc-datroway/
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261001131464/en/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-summit-therapeutics-to-evaluate-datroway%c2%ae-in-combination-with-ivonescimab-across-multiple-tumor-types/
What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-summit-therapeutics-smmt-gain-220553806.html
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-2-billion-vote-confidence-151701810.html
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4883679/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-argenx-se-argx-and-obsidian-therapeutics-obx/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-up-71-whats-next-2026-09-30/
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/astrazenecas-2-billion-vote-of-confidence-leaves-summit-therapeutics-trading-well-below-street-targets/?utm_source=snapi
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/astrazeneca-apos-2-billion-investment-190315458.html
Summit Therapeutics PLC ADR (SMMT)
September 30, 2026  |  ca.investing.comhttps://ca.investing.com/equities/summit-therapeutics-plc-news
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
September 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997738/summit-shares-jump-on-2b-strategic-investment-from-astrazeneca?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2997738
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-still-a-buy-2026-09-29/
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
September 29, 2026  |  invezz.comI
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
September 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099267?snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$225.25 -1.37 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$225.23 -0.02 (-0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$62.23 -0.60 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$62.24 +0.02 (+0.02%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$14.63 -0.74 (-4.81%)
Closing price 04:00 PM Eastern
Extended Trading
$14.68 +0.05 (+0.38%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas